Sai Kumar Chakka

Sai Kumar Chakka has had a varied and extensive career in the field of science. Sai Kumar began their career in 2005 as a Research Chemist at Cipla, where they were involved in generic drug synthesis development. In 2006, they moved to Lupin Pharmaceuticals as a Research Associate-I. From 2008 to 2011, they were a Post-Doctoral Fellow and PhD Student at the University of KwaZulu-Natal, where they synthesized chiral Tetrahydroisoquinoline (TIQ) compounds for applications in asymmetric catalysis. In 2011, they became a Post Doc Fellow at the University Health Network, where they conducted small molecule discovery of PAD inhibitors. From 2013 to 2016, they were a Research Scientist at Encycle Therapeutics Inc, where they synthesized long chain peptides, Cyclic Peptides and their Peptidomimetics. Sai Kumar then moved to Cyclenium Pharma Inc. in 2019, where they worked as a Research Scientist. Most recently, they joined Unnatural Products Inc. in 2021 as a Scientist II.

Sai Kumar Chakka completed their education history with a Doctoral degree from the University of KwaZulu-Natal in Organic Chemistry from 2008 to 2010. Prior to this, they obtained a Masters from Andhra University in Organic Chemistry from 2003 to 2005, and a Bachelors from Andhra University in Chemistry, Physics and Mathematics from 2000 to 2003.